Replies to post #338733 on NorthWest Biotherapeutics Inc (NWBO)

[Looking4aprofit]

ATLnsider,
Thanks for sharing.

[themurphman]

This is a great comparison and demonstrates why DCVax should be approved.

[Survivor2012]

Whoa ATLnsider!! Great chart to start off our Sunday morning!! I am convinced, yet again, that we have a big winner!!
Good luck to everyone!!!! FUDsters begone!!!!!!

[sentiment_stocks]

Excellent work! Your chart is quite thorough, and should prove quite useful when we examine the comparison of the DCVax-L treatment arm against those trials you’ve listed. Thank you for putting the time and effort in to assemble it. :)

[antihama]

Very nice ATLnsider. Thx!

[sukus]

Wow wow. Anyone can see and compare clearly that blinded and blended interim report of DCVax-L with other comparisons. Would the Top Line Data they will announce soon be much better than the interim report? I bet so. Would the naysayers work harder to distract? Yes certainly. All imo.

[moderation23]

Thanks for putting this together. How much does the difference between the studies WRT when the patients were randomized affect the data elements that follow?

[Bright Boy]

That is a terrific compilation of data!!! Thanks a mil!!!! Cheers, BB

[Dr Bala]

Great post. Thanks for spending time to update the comparison chart. I am sure a lot of effort went into it.

[Lykiri]

ATLnsider,

Thank you! Excellent work! Here is the list of the External Studies that Linda Liau has listed in her presentation on Nov.6, 2020.

http://my.fit.edu/~bsubrahm/Liau_Talk_UAB_11062020.pdf

Study Gilbert 2013
Study Gilbert 2014
Study Stupp
Study Weller
Study Wen

[jimmy667]

Excellent thank you. That makes my decision to continue to further accumulate easier. I love to average up. Mathematically averaging up reduces risk with appropriate mental stops in any decline except a major gap down.
If NWBO already has the data and it is not good it seems they would have made a disclosure to avoid allegations of fraud. This analysis shows that it is highly unlikely that NWBO did not acheive the primary endpoint.

[Karlchen]

Thanks, we already know that we will get approval,99%. Now we know 100%

[notbrad]

Fabulous work ATLnsider !! Many thanks.

[biosectinvestor]

Very nice ATLnsider!

[Mionaer1]

Very helpful. Thank you.

[Sojourner55]

Great chart ATL. Thanks for the effort.

[eagle8]

Thank you ATLinsider.

GLTU

[meirluc]

Great work ATLhsider. Even when 3 months on trial are subtracted from the DCVax-L trial to approximately make up the time elapsed between surgery and initiation of chemo, the blended DCVax-L trial demonstrates a superior survival pattern.

Fig 2a of the 2018 JTM publication shows for the blended trial at about a 1 year survival post chemo (about 15 months post surgery), a 75% survival rate and at 2 years post chemo (about 27 months post surgery), a 42% survival (give or take about 1%).

I am also guessing that by 39 months post chemo (36 months post surgery), the added 3 months would not have reduced the 28.2% survival rate to less than 25%.

Survival rates of 75%, 42% and 25% at 1, 2 and 3 years, are still far better than were presented or would have been expected from the four trials you used as comparisons with the DCVax-L blended data.

I also trust that the survival rates of the Treatment group will be significantly higher than those obtained from the blended trial.
In summary, it is highly unlikely that the first endpoint will fail.

[Pterion]

Amazing work. Buying more tomorrow.